^
Association details:
| Biomarker: | ASXL1 overexpression |
|---|---|
| Cancer: | Adrenal Cortex Carcinoma |
| Regimen: | (cisplatin + doxorubicin hydrochloride + etoposide IV) |
| Direction: | Resistant |
Evidence:
Source:
Title:
ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen
Published date:
09/18/2021
Excerpt:
ASXL1 overexpression was associated with recurrence and worsened prognosis in ACC. ASXL1 gain was associated with resistance to etoposide, doxorubicin and cisplatin (EDP).
